| Subcutaneous REGEN-COV antibody combination to prevent Covid-19 MP O’Brien, E Forleo-Neto, BJ Musser, F Isa, KC Chan, N Sarkar, KJ Bar, ... New England Journal of Medicine 385 (13), 1184-1195, 2021 | 467 | 2021 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 105 | 2022 |
| Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial GA Herman, MP O'Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, ... The Lancet Infectious Diseases 22 (10), 1444-1454, 2022 | 30 | 2022 |
| Hierarchical group testing for multiple infections P Hou, JM Tebbs, CR Bilder, CS McMahan Biometrics 73 (2), 656-665, 2017 | 28 | 2017 |
| Subcutaneous REGEN-COV antibody combination in early asymptomatic SARS-Cov-2 infection: a randomized clinical trial MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... MedRxiv, 2021 | 21 | 2021 |
| Array testing for multiplex assays P Hou, JM Tebbs, D Wang, CS McMahan, CR Bilder Biostatistics 21 (3), 417-431, 2020 | 15 | 2020 |
| Treatment satisfaction and burden of illness in patients with newly diagnosed multiple myeloma RM Rifkin, JA Bell, P DasMahapatra, M Hoole, M Lowe, C Curran, ... PharmacoEconomics-Open 4, 473-483, 2020 | 13 | 2020 |
| Garetosmab in fibrodysplasia ossificans progressiva: A randomized, double-blind, placebo-controlled phase 2 trial M Di Rocco, E Forleo-Neto, RJ Pignolo, R Keen, P Orcel, ... Nature medicine 29 (10), 2615-2624, 2023 | 11 | 2023 |
| Economic burden in patients with ALK+ non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors HM Lin, X Pan, P Hou, H Huang, Y Wu, K Ren, M Jahanzeb Journal of medical economics 23 (8), 894-901, 2020 | 11 | 2020 |
| Partitioning of and diversity using hierarchical Bayesian modeling of species distribution and abundance J Zhang, TO Crist, P Hou Environmental and Ecological Statistics 21 (4), 611-625, 2014 | 11 | 2014 |
| Subcutaneous REGEN-COV antibody combination in early SARS-CoV-2 infection. medRxiv (https://www. medrxiv. org/content/10.1101/2021.06. 14.21258569 v1, accessed 13 September 2021) MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Journal Website, 0 | 9 | |
| Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program HM Lin, X Pan, P Hou, S Allen, P Baumann, MJ Hochmair Future oncology 16 (15), 1031-1041, 2020 | 8 | 2020 |
| Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP) MM Lin, X Pan, P Hou, S Allen, P Baumann, MJ Hochmair Annals of Oncology 30, ii48, 2019 | 7 | 2019 |
| Covid-19 phase 3 prevention trial team effect of subcutaneous casirimivab and indemivab antibody combination vs placebo on development of symptomatic COVID-19 in early … MP O’Brien, E Forleo-Neto, N Sharkar, F Isa, P Hou, KC Chan JAMA 327, 432-441, 2022 | 5 | 2022 |
| A prospective study of key correlates for household transmission of severe acute respiratory syndrome coronavirus 2 ER Brown, MP O’Brien, B Snow, F Isa, E Forleo-Neto, KC Chan, P Hou, ... Open Forum Infectious Diseases 10 (7), ofad271, 2023 | 3 | 2023 |
| Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: A randomized, double-blind, placebo … M Di Rocco, E Forleo-Neto, R Pignolo, R Keen, P Orcel, ... medRxiv, 2023.01. 11.23284254, 2023 | 3 | 2023 |
| Garetosmab Reduces flare-ups in patients with fibrodysplasia ossificans progressiva KMC Dahir, J Mcginniss, S Mellis, RJ Sanchez, MD Rocco, R Keen, ... Journal of the Endocrine Society 5 (Supplement_1), A251-A252, 2021 | 3 | 2021 |
| Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the … X Pan, MM Lin, Y Yin, P Hou, P Baumann, M Jahanzeb Annals of Oncology 30, ii52-ii53, 2019 | 3 | 2019 |
| Comparing bortezomib-lenalidomide-dexamethasone (VRd) with carfilzomib-lenalidomide-dexamethasone (KRd) in the patients with newly diagnosed multiple myeloma (NDMM) in two … B Li, K Ren, L Shen, P Hou, Z Su, A Di Bacco, JL Hong, A Galaznik, ... Blood 132, 3298, 2018 | 3 | 2018 |
| Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection M Xu, MP O’Brien, AT Hooper, E Forleo-Neto, F Isa, P Hou, KC Chan, ... Open Forum Infectious Diseases 10 (12), ofad598, 2023 | 2 | 2023 |
